Suzetrigine (Journavx) is the first new drug approved to treat acute pain in over 20 years and the first to be classified as a selective NaV1.8 pain signal inhibitor, an alternative to opiates.

A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will be sold under the brand name Journavx.

However, given the medication’s steep price—$15.50 per 50-milligram pill—it remains to be seen whether suzetrigine has the practical potential, in addition to the medical one, to truly ...

The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class non-opioid analgesic to treat acute pain in adults. “Today’s approval ...

In two late-stage clinical trials of more than 2,000 adults who had moderate-to-severe pain after surgery, suzetrigine eased pain significantly more than a placebo without causing any serious side ...

The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class non-opioid analgesic to treat acute pain in adults.

For the first time in 25 years, the U.S. Food and Drug Administration has approved a new type of painkiller. Suzetrigine, sold as Journavx, is administered twice daily in 50-milligram oral tablets ...

Suzetrigine is the first drug to be approved in a new class of pain management medicines. It will serve as a non-opioid treatment for moderate to severe acute pain in adults.

About JOURNAVX™ (suzetrigine) JOURNAVX (suzetrigine) is a first-in-class, oral, non-opioid, highly selective pain signal inhibitor that is selective for NaV1.8 relative to other NaV channels.

Vertex Pharmaceuticals announced that Journavx will be priced at $15.50 per pill. The FDA-approved medication, available as a 50-milligram prescription tablet taken every 12 hours, offers a non ...

The Food and Drug Administration announced Thursday its approval of suzetrigine, the first new painkiller greenlit by the agency since 1998. Sold by Vertex Pharmaceuticals in 50-milligram tablets ...

Vertex Pharmaceuticals Incorporated today announced results from its Phase 2 study of suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor in people with painful ...